S&P 500   2,997.34 (+0.05%)
DOW   26,836.19 (+0.18%)
QQQ   191.58 (-0.14%)
FB   184.17 (+1.00%)
AMZN   1,750.22 (-0.88%)
CGC   21.17 (+0.09%)
NVDA   193.63 (-1.01%)
MU   44.33 (-0.74%)
BABA   169.20 (-0.41%)
TSLA   252.85 (-1.07%)
AMD   31.23 (-0.89%)
T   38.10 (-0.18%)
F   9.00 (-0.77%)
ACB   3.60 (+0.56%)
PRI   125.70 (-0.08%)
NFLX   272.20 (+2.07%)
GILD   65.59 (-0.41%)
DIS   131.64 (-0.58%)
S&P 500   2,997.34 (+0.05%)
DOW   26,836.19 (+0.18%)
QQQ   191.58 (-0.14%)
FB   184.17 (+1.00%)
AMZN   1,750.22 (-0.88%)
CGC   21.17 (+0.09%)
NVDA   193.63 (-1.01%)
MU   44.33 (-0.74%)
BABA   169.20 (-0.41%)
TSLA   252.85 (-1.07%)
AMD   31.23 (-0.89%)
T   38.10 (-0.18%)
F   9.00 (-0.77%)
ACB   3.60 (+0.56%)
PRI   125.70 (-0.08%)
NFLX   272.20 (+2.07%)
GILD   65.59 (-0.41%)
DIS   131.64 (-0.58%)
Log in

Oncolytics Biotech Stock Price, News & Analysis (NASDAQ:ONCY)

$0.49
+0.03 (+6.49 %)
(As of 10/23/2019 10:23 AM ET)
Today's Range
$0.47
Now: $0.49
$0.50
50-Day Range
$0.36
MA: $0.58
$0.74
52-Week Range
$0.35
Now: $0.49
$3.25
Volume98,087 shs
Average Volume239,479 shs
Market Capitalization$12.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCY
CUSIPN/A
CIKN/A
Phone403-670-7377

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.27 per share

Profitability

Net Income$-13,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$12.30 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive ONCY News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.


Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (NASDAQ:ONCY) posted its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter. View Oncolytics Biotech's Earnings History.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Oncolytics Biotech.

What price target have analysts set for ONCY?

2 brokerages have issued 1 year target prices for Oncolytics Biotech's shares. Their predictions range from $7.00 to $7.00. On average, they expect Oncolytics Biotech's share price to reach $7.00 in the next year. This suggests a possible upside of 1,322.8% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.

What is the consensus analysts' recommendation for Oncolytics Biotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.

Has Oncolytics Biotech been receiving favorable news coverage?

News coverage about ONCY stock has trended positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncolytics Biotech earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Oncolytics Biotech.

Are investors shorting Oncolytics Biotech?

Oncolytics Biotech saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 122,700 shares, an increase of 13.8% from the August 30th total of 107,800 shares. Based on an average trading volume of 238,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.6% of the shares of the stock are sold short. View Oncolytics Biotech's Current Options Chain.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Rita Laeufle, Chief Medical Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)

How do I buy shares of Oncolytics Biotech?

Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $0.49.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of $12.30 million. The company earns $-13,140,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. View Additional Information About Oncolytics Biotech.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]


MarketBeat Community Rating for Oncolytics Biotech (NASDAQ ONCY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel